Joanne Reekie

Summary

Affiliation: University College London
Country: UK

Publications

  1. doi request reprint A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
    J Reekie
    Research Department of Infection and Population Health, University College London Medical School, Royal Free Campus, London, UK
    HIV Med 12:259-68. 2011
  2. doi request reprint Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata
    Joanne Reekie
    University College London Medical School, London, UK
    AIDS 25:2259-68. 2011
  3. pmc Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study
    Joanne Reekie
    Medical School, University College London, London, United Kingdom
    PLoS ONE 7:e41673. 2012
  4. pmc Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study
    Daria N Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    BMC Infect Dis 12:229. 2012
  5. pmc Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
    Amanda Mocroft
    Department of Infection and Population Health, University College London, London, United Kingdom
    PLoS Med 10:e1001510. 2013
  6. doi request reprint Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Joanne Reekie
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2381-90. 2008
  7. doi request reprint Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies
    Joanne Reekie
    University College London Medical School, London, UK
    Cancer 116:5306-15. 2010
  8. pmc Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)
    Ann K Sullivan
    Directorate of Sexual Health and HIV Medicine, Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
    PLoS ONE 8:e52845. 2013

Detail Information

Publications8

  1. doi request reprint A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study
    J Reekie
    Research Department of Infection and Population Health, University College London Medical School, Royal Free Campus, London, UK
    HIV Med 12:259-68. 2011
    ..The aim of this analysis was to compare the durability of nevirapine, efavirenz and lopinavir regimens based on these measures...
  2. doi request reprint Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata
    Joanne Reekie
    University College London Medical School, London, UK
    AIDS 25:2259-68. 2011
    ..9  copies/ml) and high (≥ 10000  copies/ml)...
  3. pmc Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study
    Joanne Reekie
    Medical School, University College London, London, United Kingdom
    PLoS ONE 7:e41673. 2012
    ..This analysis aimed to establish whether there are regional differences in the mortality rate of HIV-positive individuals across Europe, and Argentina...
  4. pmc Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study
    Daria N Podlekareva
    Copenhagen HIV Programme, University of Copenhagen, Copenhagen, Denmark
    BMC Infect Dis 12:229. 2012
    ..State-of-the-art care involving the utilisation of multiple health care interventions is the basis for an optimal long-term clinical prognosis for HIV-patients. We evaluated health care for HIV patients based on four key indicators...
  5. pmc Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)
    Amanda Mocroft
    Department of Infection and Population Health, University College London, London, United Kingdom
    PLoS Med 10:e1001510. 2013
    ..Few studies have monitored late presentation (LP) of HIV infection over the European continent, including Eastern Europe. Study objectives were to explore the impact of LP on AIDS and mortality...
  6. doi request reprint Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?
    Joanne Reekie
    HIV Epidemiology and Biostatistics Group, Research Department of Infection and Population Health, Royal Free and University College Medical School, London, UK
    AIDS 22:2381-90. 2008
    ..To investigate whether HIV-infected patients on a stable and fully suppressive combination antiretroviral therapy (cART) regimen could safely be monitored less often than the current recommendations of every 3 months...
  7. doi request reprint Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies
    Joanne Reekie
    University College London Medical School, London, UK
    Cancer 116:5306-15. 2010
    ..However, conflicting data have been reported on the relationship between immunodeficiency and the development of some non-AIDS-defining malignancies...
  8. pmc Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)
    Ann K Sullivan
    Directorate of Sexual Health and HIV Medicine, Chelsea and Westminster NHS Foundation Trust, London, United Kingdom
    PLoS ONE 8:e52845. 2013
    ..A strategy is being developed in collaboration with ECDC and WHO Europe to guide the implementation of this novel public health initiative across Europe...